Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Gastroenterology | Family Medicine
Gastric Cancer Clinical Trials
A listing of Gastric Cancer medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Arizona
Scottsdale : Site Reference ID/Investigator# 24987
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
California
Beverly HIlls : Research Center
A clinical research study for patients with gastric cancer.
Beverly HIlls : Research Site
A clinical research study for patients with gastric cancer.
View More »
Bakersfield : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Duarte : City of Hope Cancer Center
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
La Jolla : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Los Angeles : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Los Angeles : Site Reference ID/Investigator# 24985
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
Stanford : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Whittier : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Colorado
Denver : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Connecticut
New Haven :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
New Haven : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
District of Columbia
Washington : Site Reference ID/Investigator# 24986
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
Florida
Jacksonville : Mayo Clinic
Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia
Pembroke Pines : Memorial Cancer Institute
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
St Petersburg :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Georgia
Savannah : Memorial University Medical Center
SWOG S1005: A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer.
View More »
Atlanta : Piedmont Hospital Research Institute
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Illinois
Elgin : Sherman Health
SWOG S1201 Phase II Randomized, Pilot Study of FOLFOX Therapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil Versus Irinotecan Hydrochloride and Docetaxel in Patients With Advanced or Metastatic Esophageal Cancer, Gastric Cancer, or Gastroesophageal Junction Cancer
View More »
Chicago :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Chicago : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Niles :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Indiana
Goshen : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Louisiana
Alexandria : Research Site
A clinical research study for patients with gastric cancer.
Massachusetts
Boston : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Boston : Dana-Farber Cancer Institute
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Boston : Massachusetts General Hospital
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Boston : Massachusetts General Hospital Cancer Center
Safety Study of MGA271 in Refractory Cancer
Minnesota
Woodbury : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Nebraska
Omaha : Nebraska Cancer Specialists, Methodist Estabrook Cancer Center
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Nevada
Henderson : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
New Jersey
Basking Ridge : Memoral Sloan Kettering Cancer Center
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
New Mexico
Albuquerque : Research Site
A clinical research study for patients with gastric cancer.
Albuquerque : Research Center
A clinical research study for patients with gastric cancer.
New York
Albany :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Commack : Memorial Sloan-Kettering Cancer Center @ Suffolk
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Jamaica : Queens Cancer Center of Queens Hospital
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
New Hyde Park : Long Island Jewish Medical Center
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
New York : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
View More »
New York : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
New York : Memorial Sloan-Kettering Cancer Center
Afatinib (BIBW 2992) in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
New York : Memorial Sloan-Kettering Cancer Center
Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers
New York : Memorial Sloan-Kettering Cancer Center 1275 York Avenue
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
New York : Weill Medical College of Cornell University
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Rockville Centre : Memorial Sloan-Kettering at Mercy Medical Center
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Sleepy Hollow : Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
North Carolina
Durham : Site Reference ID/Investigator# 24922
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
Greensboro : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Winston Salem : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Ohio
Cincinnati :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Pennsylvania
Hershey : Research Center
A clinical research study for patients with gastric cancer.
View More »
Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center
Safety Study of MGA271 in Refractory Cancer
Pittsburgh : University of Pittsburgh Cancer Institute
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Rockledge : Fox Chase Cancer Center
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors
South Carolina
Charleston : Research Center
A clinical research study for patients with gastric cancer.
Charleston : Research Site
A clinical research study for patients with gastric cancer.
View More »
Charleston : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Tennessee
Nashville :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Nashville : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Nashville : Site Reference ID/Investigator# 24983
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
Nashville : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Nashville : Sarah Cannon Research Institute
Safety Study of MGA271 in Refractory Cancer
View More »
Nashville : Sarah Cannon Research Institute
Safety Study of MGAH22 in HER2-positive Carcinomas
Texas
Dallas : Research Center
A clinical research study for patients with gastric cancer.
Houston : Research Site
A clinical research study for patients with gastric cancer.
View More »
Austin :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Bedford : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Dallas : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Garland :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Houston : UT MD Anderson Cancer Center
Chemoradiation-Induced Nausea and Emesis: Quality of Life
San Antonio : The University of Texas Health Science Center-CTRC
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors
Virginia
Fairfax :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Richmond :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Washington
Vancouver :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Wisconsin
Milwaukee : Medical College of Wisconsin
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Argentina
Rosario : Research Site
A clinical research study for patients with gastric cancer.
Australia
Douglas : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
East Bentleigh :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Elizabeth Vale : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Heidelberg :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Heidelberg : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
View More »
Herston :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Kurralta Park : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Nedlands :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Port Macquarie : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Randwick : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Sydney :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Wahroonga : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Woodville South : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Woodville South :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Belgium
Bruxelles : Research Center
A clinical research study for patients with gastric cancer.
Edegem : Research Site
A clinical research study for patients with gastric cancer.
Gent : Research Center
A clinical research study for patients with gastric cancer.
Liège : Research Site
A clinical research study for patients with gastric cancer.
View More »
Brugge : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Brussels (anderlecht) : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Brussels (woluwe-st-lambert) : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Leuven : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Leuven : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Leuven : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Liege : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Sint-niklaas : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Brazil
Barretos : Research Site
A clinical research study for patients with gastric cancer.
Belo Horizonte : Research Site
A clinical research study for patients with gastric cancer.
Fortaleza : Research Site
A clinical research study for patients with gastric cancer.
IjuĂ : Research Site
A clinical research study for patients with gastric cancer.
Porto Alegre : Research Site
A clinical research study for patients with gastric cancer.
RibeirĂŁo Preto : Research Site
A clinical research study for patients with gastric cancer.
Salvador : Research Site
A clinical research study for patients with gastric cancer.
SĂŁo Paulo : Research Site
A clinical research study for patients with gastric cancer.
SĂŁo Paulo : Research Site
A clinical research study for patients with gastric cancer.
View More »
Barretos : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Porto Alegre : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Rio de Janeiro : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Sao Paulo : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Sorocaba : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Bulgaria
Gabrovo : Research Center
A clinical research study for patients with gastric cancer.
Pleven : Research Site
A clinical research study for patients with gastric cancer.
Varna : Research Center
A clinical research study for patients with gastric cancer.
Vratsa : Research Center
A clinical research study for patients with gastric cancer.
View More »
Sofia : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Canada
Brampton : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Fredericton : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Laval : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Toronto : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Vancouver : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Chile
Santiago : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Viña Del Mar : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
China
Beijing : Beijing Cancer Hospital
A Phaseâ…ˇ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery
Beijing : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Beijing : Beijing Cancer Hospital
Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis
Chang Sha : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Changchun : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
View More »
Guangzhou : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Shanghai : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Wuhan : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Colombia
Teusaquillo : Research Center
A clinical research study for patients with gastric cancer.
Croatia
Osijek : Research Center
A clinical research study for patients with gastric cancer.
Zagreb : Research Site
A clinical research study for patients with gastric cancer.
Czech Republic
Brno : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Hradec Kralove : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Olomouc : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Olomouc : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Praha : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
View More »
Praha 2 : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Praha 2 : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Praha 8 : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Estonia
Tallinn : Research Site
A clinical research study for patients with gastric cancer.
Tallinn : Research Site
A clinical research study for patients with gastric cancer.
Finland
Tampere : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
France
Angers : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Avignon : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Besancon : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Brest Cedex : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Clichy : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
View More »
Paris : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Saint Herblain : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Toulouse : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Villejuif : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Germany
Aachen : Research Center
A clinical research study for patients with gastric cancer.
Essen : Research Site
A clinical research study for patients with gastric cancer.
Herne, NRW : Research Site
A clinical research study for patients with gastric cancer.
Leverkusen : Research Center
A clinical research study for patients with gastric cancer.
Muenchen : Research Center
A clinical research study for patients with gastric cancer.
Trier, RP : Research Site
A clinical research study for patients with gastric cancer.
View More »
Berlin : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Berlin : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Frankfurt :
An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer
Hamburg : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Landshut : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Magedburg : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Mainz : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Mannheim : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Greece
Athens : 2nd Dept of Medical Oncology, Metropolitan Hospital
Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer
Athens : 3rd Dept of Medical Oncology, Hygeia Hospital
Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer
Athens : Oncology Section, Dept of Clinical Therapeutics, General Hospital of Athens "Alexandra"
Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer
Athens : 1st Dept of Medical Oncology, Metropolitan Hospital
Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer
Athens : 3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital
Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer
View More »
Athens : Division of Oncology, 2nd Dept of Internal Medicine, University Hospital "Attikon"
Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer
Heraklio : Dept of Medical Oncology, University Hospital of Heraklion
Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer
Ioannina : Dept of Medical Oncology, Ioannina University Hospital
Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer
Patras : Division of Oncology, Dept of Internal Medicine, University Hospital of Patras
Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer
Thessaloniki : Dept of Medical Oncology, Papageorgiou General Hospital
Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer
Hong Kong
Hong Kong : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Hungary
Budapest : Research Center
A clinical research study for patients with gastric cancer.
Gyor : Research Center
A clinical research study for patients with gastric cancer.
NyĂregyháza : Research Site
A clinical research study for patients with gastric cancer.
Pécs : Research Center
A clinical research study for patients with gastric cancer.
Szeged : Research Center
A clinical research study for patients with gastric cancer.
Székesfehérvár : Research Center
A clinical research study for patients with gastric cancer.
View More »
Budapest : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Budapest : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Pecs : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Szeged : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Szolnok : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Szombathely : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Veszprem : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Zalaegerszeg : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
India
Bangalore :
A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
Bangalore : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Chennai : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Hyderabad : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Nagpur :
A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
View More »
Nagpur : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
New Delhi :
A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
Pune : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Vellore : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Vishakpatnam :
A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
Israel
Beer Sheva : Research Site
A clinical research study for patients with gastric cancer.
Jerusalem : Research Center
A clinical research study for patients with gastric cancer.
Kfar Saba : Research Center
A clinical research study for patients with gastric cancer.
Ramat Gan : Research Center
A clinical research study for patients with gastric cancer.
Tel Aviv : Research Center
A clinical research study for patients with gastric cancer.
Italy
Milano : Research Site
A clinical research study for patients with gastric cancer.
Milano : Research Center
A clinical research study for patients with gastric cancer.
Modena : Research Center
A clinical research study for patients with gastric cancer.
Potenza : Research Site
A clinical research study for patients with gastric cancer.
Reggio Emilia : Research Site
A clinical research study for patients with gastric cancer.
Rimini : Research Center
A clinical research study for patients with gastric cancer.
View More »
Ancona : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Ancona : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Bologna : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Catanzaro : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Catanzaro : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Catanzaro : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Firenze : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Firenze : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Florence : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Milano : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Milano : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Milano : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Pisa : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Pisa : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Pisa : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Pisa : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Prato : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Reggio Emilia : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Roma : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Roma : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Torino : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Udine : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Udine : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Japan
Aichi : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Chiba : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Kashiwa : Updated
A Phase I Study of E7050 in Subjects With Solid Tumors
Nagoya : Updated
A Phase I Study of E7050 in Subjects With Solid Tumors
Sapporo-shi : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
View More »
Shizuoka : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Sunto : Updated
A Phase I Study of E7050 in Subjects With Solid Tumors
Takatsuki-shi : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Tokyo : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Korea, Republic of
Anyang-si : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Bundang City : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Daegu : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Incheon : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Jeollanam-do : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
View More »
Jeonju-si : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Seongnam : Seoul National University Bundang Hospital
A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors
Seongnam-si : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Seoul : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Seoul : Seoul National University Hospital
A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors
Seoul : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Seoul :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Seoul : Investigational Site Number 410001
Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy
Seoul : Administrative Office
Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer
Seoul : Asan Medical Center
Dovitinib for Gastric Cancer With FGFR2 Amplification
Seoul : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Seoul : Seoul National University Hospital
Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy
Seoul : Yonsei University Gangnam Severance Hospital
Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy
Seoul : Seoul National University Hospital
Safety Study of MGAH22 in HER2-positive Carcinomas
Malaysia
Kuala Lumpur : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Sabah : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Mexico
Chihuahua : Research Center
A clinical research study for patients with gastric cancer.
Mexico City : Research Site
A clinical research study for patients with gastric cancer.
View More »
Distrito Federal : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Mexico City : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Monterrey : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Oaxaca : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Netherlands
Amsterdam : Nederlands Kanker Instituut/Antoni van Leeuwenhoek Ziekenhuis
Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)
New Zealand
Auckland : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Panama
Panama : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Peru
Arequipa : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Lima : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Trujillo : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Philippines
Cebu : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Manila : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Pasig City : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Quezon City, Luzon : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Poland
Gdansk : Research Site
A clinical research study for patients with gastric cancer.
Lodz : Research Site
A clinical research study for patients with gastric cancer.
Olsztyn : Research Site
A clinical research study for patients with gastric cancer.
Szczecin : Research Site
A clinical research study for patients with gastric cancer.
Warszawa : Research Site
A clinical research study for patients with gastric cancer.
View More »
Gdansk : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Krakow : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Krakow : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Poznan : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Warsaw : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Portugal
Aveiro : Research Center
A clinical research study for patients with gastric cancer.
Barreiro : Research Site
A clinical research study for patients with gastric cancer.
Coimbra : Research Center
A clinical research study for patients with gastric cancer.
Lisboa : Research Site
A clinical research study for patients with gastric cancer.
Porto : Research Site
A clinical research study for patients with gastric cancer.
View More »
Porto : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Romania
Baia Mare : Research Center
A clinical research study for patients with gastric cancer.
Cluj-Napoca : Research Site
A clinical research study for patients with gastric cancer.
Iasi : Research Center
A clinical research study for patients with gastric cancer.
Onesti : Research Center
A clinical research study for patients with gastric cancer.
View More »
Bucharest : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Cluj-napoca : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Russia
Barnaul : Research Center
A clinical research study for patients with gastric cancer.
Moscow : Research Site
A clinical research study for patients with gastric cancer.
Saint Petersburg : Research Center
A clinical research study for patients with gastric cancer.
Saint Petersburg : Research Site
A clinical research study for patients with gastric cancer.
Saint-Petersburg : Research Site
A clinical research study for patients with gastric cancer.
Russian Federation
Arkhangelsk : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Ivanovo : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Pyatigorsk : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Ryazan : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
St Petersburg : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
View More »
Stavropol : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Tula : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Tula : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Serbia
Belgrade : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
NIS : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Sremska Kamenica : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Singapore
Singapore :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
South Africa
Cape Town : Research Site
A clinical research study for patients with gastric cancer.
Cape Town : Research Site
A clinical research study for patients with gastric cancer.
Durban : Research Center
A clinical research study for patients with gastric cancer.
Groenkloof Pretoria : Research Center
A clinical research study for patients with gastric cancer.
Port Elisabeth : Research Site
A clinical research study for patients with gastric cancer.
Pretoria : Research Center
A clinical research study for patients with gastric cancer.
View More »
Johannesburg : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Spain
Barcelona : Research Site
A clinical research study for patients with gastric cancer.
Barcelona : Research Site
A clinical research study for patients with gastric cancer.
Barcelona : Research Site
A clinical research study for patients with gastric cancer.
Barcelona : Research Center
A clinical research study for patients with gastric cancer.
Barcelona : Research Center
A clinical research study for patients with gastric cancer.
Elche : Research Center
A clinical research study for patients with gastric cancer.
Madrid : Research Center
A clinical research study for patients with gastric cancer.
Madrid : Research Site
A clinical research study for patients with gastric cancer.
Madrid : Research Center
A clinical research study for patients with gastric cancer.
Madrid : Research Center
A clinical research study for patients with gastric cancer.
Madrid : Research Center
A clinical research study for patients with gastric cancer.
Malaga : Research Site
A clinical research study for patients with gastric cancer.
Sabadell : Research Center
A clinical research study for patients with gastric cancer.
Valencia : Research Center
A clinical research study for patients with gastric cancer.
View More »
A Coruna : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Barcelona : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Barcelona : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Barcelona : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Barcelona : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Elche : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Madrid : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Madrid : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Madrid : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Madrid : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Oviedo : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Oviedo : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Santander : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Santander : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Santander : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Santiago de Compostela : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Sevilla : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Sevilla : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Valencia : Updated
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer
Zaragoza : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Zaragoza : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Switzerland
Bern : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Luzern : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
ZĂĽrich : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Taiwan
Kueishan :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Tainan :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Taipei :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Taipei : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Thailand
Bangkok : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Bangkok :
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative Gastroesophageal Cancer
Chiang Rai : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Hat Yai : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Lopburi : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Turkey
Adana : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Ankara :
A Study of the Combination of Oxaliplatin, Capecitabine and Herceptin (Trastuzumab) and Chemoradiotherapy in The Adjuvant Setting in Operated Patients With HER2+ Gastric or Gastro-Esophageal Junction Cancer (TOXAG Study)
Gaziantep :
A Study of the Combination of Oxaliplatin, Capecitabine and Herceptin (Trastuzumab) and Chemoradiotherapy in The Adjuvant Setting in Operated Patients With HER2+ Gastric or Gastro-Esophageal Junction Cancer (TOXAG Study)
Istanbul :
A Study of the Combination of Oxaliplatin, Capecitabine and Herceptin (Trastuzumab) and Chemoradiotherapy in The Adjuvant Setting in Operated Patients With HER2+ Gastric or Gastro-Esophageal Junction Cancer (TOXAG Study)
Istanbul : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
View More »
Izmir : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Izmir : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Konya :
A Study of the Combination of Oxaliplatin, Capecitabine and Herceptin (Trastuzumab) and Chemoradiotherapy in The Adjuvant Setting in Operated Patients With HER2+ Gastric or Gastro-Esophageal Junction Cancer (TOXAG Study)
Shhiye, Ankara : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Shhiye, Ankara :
A Study of the Combination of Oxaliplatin, Capecitabine and Herceptin (Trastuzumab) and Chemoradiotherapy in The Adjuvant Setting in Operated Patients With HER2+ Gastric or Gastro-Esophageal Junction Cancer (TOXAG Study)
Shhiye, Ankara : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Ukraine
Cherkassy : Research Center
A clinical research study for patients with gastric cancer.
Chernivtsiy : Research Center
A clinical research study for patients with gastric cancer.
Dnepropetrovsk : Research Center
A clinical research study for patients with gastric cancer.
Donetsk : Research Center
A clinical research study for patients with gastric cancer.
Kharkiv : Research Center
A clinical research study for patients with gastric cancer.
Kyiv : Research Site
A clinical research study for patients with gastric cancer.
Lutsk : Research Center
A clinical research study for patients with gastric cancer.
Lviv : Research Center
A clinical research study for patients with gastric cancer.
Sumy : Research Center
A clinical research study for patients with gastric cancer.
Uzhgorod : Research Center
A clinical research study for patients with gastric cancer.
Zaporizzhya : Research Center
A clinical research study for patients with gastric cancer.
View More »
Cherkassy : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
United Kingdom
London : Research Center
A clinical research study for patients with gastric cancer.
Rhyl : Research Center
A clinical research study for patients with gastric cancer.
View More »
Aberdeen : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Bristol : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Cardiff : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Denbighshire : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Glasgow : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Leicester : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
London : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
London : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
London : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
London and Surrey : Royal Marsden NHS Foundation Trust
Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours
Maidstone : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Manchester : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Manchester : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Manchester : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Southampton : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Southampton : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Sutton : Updated
A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric)
Sutton : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Sutton : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Weston Super Mare : Updated
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
Wolverhampton : Updated
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
Wolverhampton : Research Site
Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients